Hematopoietic Stem Cell TransplantationHematopoietic Stem CellsTransplantation, HomologousStem Cell TransplantationTransplantation, AutologousGraft vs Host DiseaseTransplantation ConditioningStem CellsPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsGraft SurvivalBone Marrow TransplantationTransplantation ChimeraTissue DonorsTreatment OutcomeCord Blood Stem Cell TransplantationHematopoiesisHistocompatibility TestingMyeloablative AgonistsWhole-Body IrradiationHematopoietic Stem Cell MobilizationHistocompatibilityBusulfanAntigens, CD34Liver TransplantationRetrospective StudiesGraft vs Leukemia EffectChimerismLeukemiaRecurrenceCell DifferentiationImmunosuppressive AgentsBone Marrow CellsMesenchymal Stem Cell TransplantationHematologic DiseasesRemission InductionCombined Modality TherapyHepatic Veno-Occlusive DiseaseHLA AntigensTime FactorsMultiple MyelomaCell TransplantationSiblingsCell LineageUnrelated DonorsVidarabineKidney TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesSurvival RateStem Cell NicheEmbryonic Stem CellsTransplantation ImmunologyGraft vs Tumor EffectDisease-Free SurvivalAdult Stem CellsFlow CytometrySurvival AnalysisMice, Inbred C57BLMelphalanSevere Combined ImmunodeficiencyLymphocyte TransfusionBone MarrowTransplantation, IsogeneicFetal BloodCyclophosphamideColony-Forming Units AssayPrecursor Cell Lymphoblastic Leukemia-LymphomaGranulocyte Colony-Stimulating FactorSalvage TherapyAntilymphocyte SerumCytomegalovirus InfectionsFollow-Up StudiesAnemia, AplasticLeukemia, Myelogenous, Chronic, BCR-ABL PositiveDonor SelectionLymphocyte DepletionT-LymphocytesAllograftsAcute DiseaseCells, CulturedAntineoplastic Combined Chemotherapy ProtocolsCell SeparationGraft RejectionMesenchymal Stromal CellsImmunosuppressionPluripotent Stem CellsHeart TransplantationCell ProliferationMultipotent Stem CellsStem Cell FactorOpportunistic InfectionsLymphoma, Non-HodgkinImmunocompromised HostLymphoproliferative DisordersTransplantationOrgan TransplantationPrognosisMice, SCIDRisk Factors